HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Selectivity for ovarian cancer of an improved serum radioimmunoassay for human ovarian tumor-associated antigen NB/70K.

Abstract
An improved NB/70K assay which can be used to reproducibly and accurately measure the NB/70K content of unextracted serum samples has been developed. Analysis of pretreatment serum samples has indicated that the NB/70K assay shows selectivity for ovarian cancer with respect to nonmalignant ovarian cysts and tumors as well as controls; if one considers 10 units of NB/70K as a significant level of antigen, then there are no false positives in the benign and control groups, while 10 of 21 in the ovarian cancer group have significant NB/70K levels. When NB/70K levels of ovarian cancer patients are compared to those of patients with non-ovarian malignant disease, only 4 of 23 patients with non-ovarian cancers had significantly elevated NB/70K levels. However, none of these 4 false positives had levels greater than 20 units.
AuthorsS Knauf, P Taillon-Miller, B F Helmkamp, T A Bonfiglio, J B Beecham
JournalGynecologic oncology (Gynecol Oncol) Vol. 17 Issue 3 Pg. 349-55 (Mar 1984) ISSN: 0090-8258 [Print] United States
PMID6706232 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, Neoplasm
  • Immune Sera
Topics
  • Animals
  • Antigens, Neoplasm (analysis, immunology)
  • Female
  • Humans
  • Immune Sera (immunology)
  • Ovarian Neoplasms (immunology)
  • Rabbits (immunology)
  • Radioimmunoassay (methods)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: